KTRA vs. PTIX, YMTX, HOTH, KA, PCSA, AIMD, IBIO, HILS, LIXT, and PXMD
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Protagenic Therapeutics (PTIX), Yumanity Therapeutics (YMTX), Hoth Therapeutics (HOTH), Kineta (KA), Processa Pharmaceuticals (PCSA), Ainos (AIMD), iBio (IBIO), Hillstream BioPharma (HILS), Lixte Biotechnology (LIXT), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical preparations" industry.
Protagenic Therapeutics (NASDAQ:PTIX) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
In the previous week, Protagenic Therapeutics and Protagenic Therapeutics both had 1 articles in the media. Kintara Therapeutics' average media sentiment score of 0.00 equaled Protagenic Therapeutics'average media sentiment score.
Protagenic Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
Protagenic Therapeutics' return on equity of 0.00% beat Kintara Therapeutics' return on equity.
Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Kintara Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 4.8% of Kintara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Kintara Therapeutics received 16 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.
Summary
Protagenic Therapeutics beats Kintara Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
